COLORECTAL LIVER METASTASES AFTER CHEMOEMBOLIZATION WITH MICROSPHERES: PROGNOSTIC VALUE OF LESION FEATURES AND CHOICE OF THE OBJECTIVE RESPONSE CRITERIA

Objective: to study the possibilities of Choi criteria in evaluating the objective response of metastatic colorectal cancer to transarterial chemoembolization (TACE), as well as to study the influence of the size and density of metastatic lesions on the posttreatment prognosis of the disease. Material and methods. CT data of 78 patients with colorectal cancer metastatic liver lesions before and after TACE with drug-eluted microspheres was analyzed. The posttreatment changes in the size and density of lesions were statistically analyzed. Evaluation of the treatment results was made according to Choi criteria and according to RECIST criteria. The effectiveness of both criteria was compared by analyzing progression-free survival (PFS) using the Kaplan-Meier method. The analysis of the influence of pretreatment size and density of lesions on the time to progression was done. Results. There was no significant reduction in the size of the liber lesions after TACE, but the density of the lesions decreased. According to the RECIST criteria, the stable disease was established in the majority of patients (73,1%). According to the Choi criteria, the majority of patients (65,4%) had a partial response. Response category coincided in 37,1% of observations. There were no significant differences in PFS between patients with different response categories according to RECIST criteria (p=0,052). PFS in patients with different response categories according to Choi criteria was different (p=0,000). There were no significant differences in PFS between patients with different sizes of foci before treatment (p=0,833). A higher density of foci before treatment provides higher PFS values (p=0,001). The sizes of lesions remain stable after TACE, but their density decreases. The Choi criteria are more effective in evaluating the TACE results of colorectal liver metastases than the RECIST criteria. The pretreatment lesions size is not a prognostic factor. Higher initial lesions density is associated with better treatment prognosis.

1. Edmunson H., Craig J. Neoplasms of the liver// Schiff L. (ed.) Diseases of the liver. 8th ed. Lippincott, Philadelphia, 1987. 1109 р.

2. Yan T.D., Padang R., Morris D.L. Long-term results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases // J. Am. Coll. Surg. 2006. Vol. 202 (1). Р. 100–111.

3. Liapi E., Geschwind J.F. Chemoembolization for primary and metastatic liver cancer // Cancer J. 2010. Vol. 16 (2). Р. 156–162.

4. Fiorentini G., Aliberti C., Turrisi G., Del Conte A., Rossi S., Benea G., Giovanis P. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study // In Vivo. 2007. Vol. 21 (6). Р. 1085–1091.

5. Martin R.C., Joshi J., Robbins K., Tomalty D., Bosnjakovik P., Derner M., Padr R., Rocek M., Scupchenko A., Tatum C. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study // Ann. Surg. Oncol. 2011. Vol. 18 (1). Р. 192–198.

6. Richardson A.J., Laurence J.M., Lam V.W. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review // J. Vasc. Interv. Radiol. 2013. Vol. 24 (8). Р. 1209–1217.

7. Силантьева Н.К., Агабабян Т.А., Березовская Т.П., Гришина О.Г. КТ-оценка эффектов химио- и лучевой терапии злокачественных опухолей // Медицинская визуализация. 2014. № 6. С. 59–74. [Silanteva N.K., Agababian T.A., Berezovskaya T.P. et al. CT Assessment of Tumor Response to Chemo- and Radiotherapy. Meditsinskaya vizualizatsiya, 2014, No. 6, pp. 59–74. (In Russ.)].

8. Современные стандарты анализа лучевых изображений: руководство для врачей/ Т. Н. Трофимова, А. В. Мищенко, Б. А. Минько и др.; под ред. проф. Т. Н. Трофимовой. СПб., 2017. 300 с.: ил. [Sovremennye standarty analiza luchevyh izobrazhenij: rukovodstvo dlya vrachej/ T. N. Trofimova, A. V. Mishchenko, B. A. Min’ko et al.; pod red. prof. T. N. Trofimovoj. Saint Petersburg, 2017. 300 s.: il. (In Russ.)].

9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada // J. Natl. Cancer Inst.2000. Vol. 92 (3). Р. 205–216.

10. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 2000. Vol. 45 (2). Р. 228–247.

11. Mantatzis M., Kakolyris S., Amarantidis K., Karayiannakis A., Prassopoulos P. Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? // Eur. Radiol. 2009. Vol. 19 (7). Р. 1809–1816.

12. Galizia M.S., Töre H.G., Chalian H., Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumet-ric analysis: effect on liver transplantation eligibility // Acad. Radiol. 2011. Vol. 18 (12). Р. 1555–1560.

13. Forner A., Ayuso C., Varela M., Rimola J., Hessheimer A.J., de Lope C.R., Reig M., Bianchi L., Llovet J.M., Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? // Cancer. 2009. Vol. 115 (3). Р. 616–623.

14. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma // Semin. Liver. Dis. 2010. Vol. 30 (1). Р. 52–60.

15. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., Rodés J.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver // J. Hepatol. 2001. Vol. 35 (3). Р. 421–430.

16. Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., Chen L.L., Podoloff D.A., Benjamin R.S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria // J. Clin. Oncol. 2007. Vol. 25 (13). Р. 1753–1759.

17. Soyer P., Poccard M., Boudiaf M., Abitbol M., Hamzi L., Panis Y., Valleur P., Rymer R. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology. 2004. Vol. 231 (2). Р. 413–420.

18. Kamel I.R., Liapi E., Reyes D.K., Zahurak M., Bluemke D.A., Geschwind J.F. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging // Radiology. 2009. Vol. 250 (2). Р. 466–473.

19. Gonzalez-Guindalini F.D., Botelho M.P., Harmath C.B., Sandrasegaran K., Miller F.H., Salem R., Yaghmai V. Assessment of liver tumor response to therapy: role of quantitative imaging // Radiographics. 2013. Vol. 33 (6). Р. 1781–1800.

20. Scarsbrook A.F., Ganeshan A., Statham J., Thakker R.V., Weaver A., Talbot D., Boardman P., Bradley K.M., Gleeson F.V., Phillips R.R. Anatomic and functional imaging of metastatic carcinoid tumors // Radiographics. 2007. Vol. 27 (2). Р. 455–477.

21. Chalian H., Töre H.G., Horowitz J.M., Salem R., Miller F.H., Yaghmai V. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0 // Radiographics. 2011. Vol. 31 (7). Р. 2093–2105.

22. Belton A.L., Saini S., Liebermann K., Boland G.W., Halpern E.F. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements // Clin. Radiol. 2003. Vol. 58 (4). Р. 311–314.

23. Martin R.C., Robbins K., Tomalty D., O’Hara R., Bosnjakovic P., Padr R., Rocek M., Slauf F., Scupchenko A., Tatum C. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report // World J. Surg. Oncol. 2009. No 7. Р. 80.

24. Narayanan G., Barbery K., Suthar R., Guerrero G., Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer // Anticancer Res. 2013. Vol. 33 (5). Р. 2077–2083.

25. Eichler K., Zangos S., Mack M.G., Hammerstingl R., Gruber-Rouh T., Gallus C., Vogl T.J. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) // Int. J. Oncol. 2012. Vol. 41 (4). Р. 1213–1220.

26. Tochetto S.M., Rezai P., Rezvani M., Nikolaidis P., Berggruen S., Atassi B., Salem R., Yaghmai V. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET? // Radiology. 2010. Vol. 255 (1). Р. 164–172.

27. Chun Y.S., Vauthey J.N., Boonsirikamchai P., Maru D.M., Kopetz S., Palavecino M., Curley S.A., Abdalla E.K., Kaur H., Charnsangavej C., Loyer E.M. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases // JAMA. 2009. Vol. 302 (21). Р. 2338–2344.

28. Chung W.S., Park M.S., Shin S.J., Baek S.E., Kim Y.E., Choi J.Y., Kim M.J. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria // Am. J. Roentgenol.2012. Vol. 199 (4). Р. 809–815.

29. Ebied O.M., Federle M.P., Carr B.I., Pealer K.M., Li W., Amesur N., Zajko A. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma // Cancer. 2003. Vol. 97 (4). Р. 1042–1050.

30. Kim J.H., Yoon H.K., Ko G.Y., Gwon D.I., Jang C.S., Song H.Y., Shin J.H., Sung K.B. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization // Radiology. 2010. Vol. 255 (1). Р. 270–277.